Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Eur J Surg Oncol. 2021 Feb;47(2):463-469. doi: 10.1016/j.ejso.2020.05.006. Epub 2020 May 12.
Radical cystectomy (RC) is often performed for T1 variant histology bladder cancer (VHBC), based on weak clinical evidence. We tested for cancer specific survival (CSS) differences after RC between T1 VHBC vs. urothelial carcinoma of the urinary bladder (UBC).
Within the Surveillance, Epidemiology and End Results registry (SEER, 2001-2016), we retrospectively identified T1N0M0 VHBC (adenocarcinoma, squamous cell carcinoma [SqCC], neuroendocrine carcinoma and other VHBC) and UBC patients. Kaplan-Meier plots, multivariate Cox regression models (CRM) with inverse probability treatment weighting (IPTW) and competing risks regression (CRR) tested CSS rates after RC in stage T1 vs. no-RC according to VHBC type and UBC.
Of all 37,528 T1N0M0 bladder cancer patients, 1726 (4.6%) harboured VHBC. Of those, 598 (1.6%) had SqCC, 409 (1.1%) adenocarcinoma, 249 (0.7%) neuroendocrine carcinoma and 470 (1.3%) other VHBC. RC was performed in 7.4-11.0% of VHBC vs. 5.1% of high grade UBC patients. In patients with neuroendocrine and SqCC, RC was associated with higher CSS rates than any other surgical treatment modality (both p ≤ 0.01). Sixty-month CSS was 100% vs. 67% in neuroendocrine and 86% vs. 66% in SqCC in unadjusted analyses and remained statistically significantly higher in multivariate, IPTW adjusted analyses and in multivariate CRR. No difference was recorded for adenocarcinoma or other VHBC types.
RC for stage T1N0M0 VHBC appears to provide a protective effect with respect to CSS in patients with SqCC and neuroendocrine carcinoma, but not in adenocarcinoma or other VHBC.
基于薄弱的临床证据,常对 T1 变异型组织学膀胱癌(VHBC)施行根治性膀胱切除术(RC)。我们检测了 RC 后 T1 VHBC 与尿路上皮膀胱癌(UBC)之间的癌症特异性生存(CSS)差异。
在监测、流行病学和最终结果(SEER,2001-2016)登记处,我们回顾性地确定了 T1N0M0 VHBC(腺癌、鳞状细胞癌[SqCC]、神经内分泌癌和其他 VHBC)和 UBC 患者。Kaplan-Meier 图、多变量 Cox 回归模型(CRM)与逆概率治疗加权(IPTW)和竞争风险回归(CRR)根据 VHBC 类型和 UBC 检测了 RC 后 T1 期与非 RC 期的 CSS 率。
在所有 37528 例 T1N0M0 膀胱癌患者中,1726 例(4.6%)患有 VHBC。其中,598 例(1.6%)为 SqCC,409 例(1.1%)为腺癌,249 例(0.7%)为神经内分泌癌,470 例(1.3%)为其他 VHBC。RC 在 VHBC 患者中的实施率为 7.4-11.0%,而高级别 UBC 患者为 5.1%。在神经内分泌癌和 SqCC 患者中,RC 与任何其他手术治疗方式相比,CSS 率更高(均 p ≤ 0.01)。未调整分析中,RC 的 60 个月 CSS 为 100% vs. 67%,SqCC 为 86% vs. 66%,在多变量、IPTW 调整分析和多变量 CRR 中仍然具有统计学显著意义。未记录到腺癌或其他 VHBC 类型的差异。
RC 治疗 T1N0M0 VHBC 似乎对 SqCC 和神经内分泌癌患者的 CSS 具有保护作用,但对腺癌或其他 VHBC 类型无作用。